Home example 2 - Pharmamarketeer

overig

GDPR: welk risico lopen bedrijven écht?

In de afgelopen dagen zijn we allemaal murw geslagen door een schier eindeloze stroom van GDPR-mailtjes. Veel bedrijven vragen zich ondertussen vertwijfeld af of zij niet ook zulke mails zouden moeten versturen.

marketingfacts.nl

5 x gelezen

marketing

Before You Start an AI Strategy Make the Case To Stop

Before You Start an AI Strategy Make the Case To Stop Helping clients get ready to integrate generative AI, I’ve noticed something interesting. After walking through use cases and how the technology could impact the...

Content Marketing Institute

5 x gelezen

onderzoek

Foamix’s treatment for common skin condition meets late-stage trial goals

Foamix Pharmaceuticals Ltd said on Wednesday its experimental foam treatment for rosacea, a common skin condition that causes acne-like bumps and redness on the face, met the main goals of two late-stage clinical trials.

Reuters Health

5 x gelezen

farma-industrie

Sun Pharma drops to 6-year low on report of another whistleblower complaint

News of a second complaint filed to Indian regulators sent the drugmaker’s shares tumbling yet again, this time to their lowest point in about six years. The new complaint was said focus on a large number of...

FiercePharma

5 x gelezen

wet- en regelgeving

Roche’s Tecentriq combo scoops up European approval in first-line metastatic lung cancer

Roche has announced the approval of the European Commission for its PD-L1 inhibitor Tecentriq (atezolizumab) when used in combination with Avastin (bevacizumab), paclitaxel and carboplatin as a first-line treatment for...

InPharm.com

5 x gelezen

onderzoek

Roche’s Tecentriq meets primary endpoint in Phase 3 bladder cancer trial

Roche has said its immunotherapy drug Tecentriq (Atezolizumab), when used in combination with platinum-based chemotherapy, significantly reduced the risk of disease worsening and death in a Phase 3 trial of patients...

InPharm.com

5 x gelezen

wet- en regelgeving

FDA grants Johnson & Johnson’s Invokana new kidney disease approval

Johnson & Johnson’s Invokana (canaglifolozin) has become the only drug in the SGLT2 inhibitor class to be approved by the FDA for treating diabetic kidney disease (DKD) and to reduce the risk of hospitalisation for...

InPharm.com

5 x gelezen

marketing

Communiceren over corona, de opmerkelijkste social berichten

Corona Weinig kanalen zijn zo geschikt om informatie over corona te delen als sociale media. Een verzameling goede en vreselijke voorbeelden. Juist in tijden van quarantaine en verplicht thuiswerken zijn sociale media...

Adformatie Artikelen

5 x gelezen

technologie

Artificial intelligence can make personality judgments based on our photographs

Russian researchers from HSE University and Open University for the Humanities and Economics have demonstrated that artificial intelligence is able to infer people’s personality from ‘selfie’...

EurekAlert

5 x gelezen

marketing

21 SEO Tips, Tactics, and Trends for Website Content in 2021

Don’t expect 2021 to bring relief from the merciless slide of organic content down search engine results pages. But with a little attention to these 21 SEO tips, tactics, and trends, you can protect your rankings...

Content Marketing Institute

5 x gelezen

Latest articles

GDPR: welk risico lopen bedrijven écht?

Before You Start an AI Strategy Make the Case To Stop

Foamix’s treatment for common skin condition meets late-stage trial goals

Sun Pharma drops to 6-year low on report of another whistleblower complaint

Roche’s Tecentriq combo scoops up European approval in first-line metastatic lung cancer

Roche’s Tecentriq meets primary endpoint in Phase 3 bladder cancer trial

FDA grants Johnson & Johnson’s Invokana new kidney disease approval

Communiceren over corona, de opmerkelijkste social berichten

Artificial intelligence can make personality judgments based on our photographs

21 SEO Tips, Tactics, and Trends for Website Content in 2021

Wekelijkse highlights per e-mail

Algemene informatie